AbbVie Inc. (TSX:ABBV)
Canada · Delayed Price · Currency is CAD | Market Cap | 540.60B +19.4% |
| Revenue (ttm) | 87.69B +9.5% |
| Net Income | 5.02B -13.3% |
| EPS | 2.83 -13.2% |
| Shares Out | n/a |
| PE Ratio | 107.73 |
| Forward PE | 14.46 |
| Dividend | 1.19 (3.92%) |
| Ex-Dividend Date | Apr 15, 2026 |
| Volume | 9,707 |
| Open | 32.01 |
| Previous Close | 30.31 |
| Day's Range | 32.00 - 32.31 |
| 52-Week Range | 26.01 - 34.48 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 27, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
Apogee deal gives positive readthrough to Evommune pipeline, says Clear Street
Clear Street reiterated a Buy rating and $53 price target on Evommune (EVMN), saying Abbvie’s (ABBV) proposed acquisition of Apogee (APGE) provides a positive readthrough to Evommune’s pipeline. In pa...
Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE
Micron (MU) is entering a new strategic partnership with Anthropic as Needham raises its price target on the AI memory stock. Credo Technology (CRDO) gets a new bull in Evercore ISI after it initiated...
AbbVie to Buy Apogee Therapeutics for $10.9 Billion
Bloomberg Intelligence's Sam Fazeli discusses AbbVie's $10.9 billion acquisition of Apogee Therapeutics. The deal enhances AbbVie's presence in dermatology by adding treatments for atopic dermatitis, ...
AbbVie Transcript: M&A announcement
The acquisition brings a portfolio of differentiated, long-acting antibody assets to strengthen the immunology and respiratory pipelines, with the lead asset targeting atopic dermatitis and potential mega blockbuster sales. The $10.9B all-cash deal is expected to be accretive by 2032, leveraging clinical and commercial synergies for long-term growth.
AbbVie Slides: M&A announcement
AbbVie has posted slides in relation to its latest quarterly earnings report, which was published on June 22, 2026.
AbbVie Press release: M&A announcement
AbbVie issued a press release on June 22, 2026, disclosing material business information to investors.
Apogee acquisition is ‘net negative’ for Regeneron, says RBC Capital
RBC Capital keeps a Sector Perform rating and a $707 price target on Regeneron (REGN) but notes that the acquisition of Apogee Therapeutics (APGE) by AbbVie (ABBV) announced this morning…
AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash
AbbVie has agreed to buy Apogee Therapeutics for about $10.9 billion in cash in a deal that bolsters the biopharmaceutical company's immunology and inflammation portfolio.
AbbVie to acquire Apogee Therapeutics for $10.9B in cash
07:00 EDT AbbVie (ABBV) to acquire Apogee Therapeutics (APGE) for $10.9B in cash
AbbVie to acquire Apogee Therapeutics for $135.11 per share in cash, or $10.9B
AbbVie (ABBV) and Apogee Therapeutics (APGE) announced they have entered into a definitive agreement under which AbbVie will acquire Apogee and its diverse pipeline of multiple clinical-stage candidat...
Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.
AbbVie will acquire the clinical-stage biotech's pipeline of candidates for inflammatory and immunological diseases.
AbbVie strikes $10.9 billion deal for Apogee Therapeutics
AbbVie will acquire biotech Apogee Therapeutics for $10.9 billion in cash, they said on Monday, as the company builds its next-generation immunology pipeline.
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
Proposed acquisition adds a diverse pipeline of assets focused on elevating the standard of care for patients with dermatologic, respiratory and other related inflammatory and immunological diseases A...
Canaccord sees potential Apogee buyout as ‘huge win’ for sector
Canaccord analyst Edward Nash says AbbVie’s (ABBV) reported $10.9B takeover of Apogee Therapeutics (APGE) equates to roughly $144 per share. Apogee in premarket trading is up 50%, or $45.23, to…
BTIG says others may be interested in Apogee Therapeutics
BTIG analyst Julian Harrison says AbbVie (ABBV) can leverage its existing dermatology channels and compete in atopic dermatitis beyond JAK inhibitors with an acquisition of Apogee Therapeutics (APGE)....
AbbVie bid for Apogee Therapeutics makes sense, says Wells Fargo
A reported bid by AbbVie (ABBV) for Apogee Therapeutics (APGE) makes sense given Apogee’s strong fit in the M&A screen, and such a transaction would likely be viewed positively for…
AbbVie near deal to acquire Apogee Therapeutics, FT reports
AbbVie (ABBV) is nearing a deal to acquire Apogee Therapeutics (APGE) for $10.9B in cash, Financial Times reports, citing people familiar with the matter. A deal could be announced as…
‘A Solid Fit’: JPMorgan Backs AbbVie’s Potential $11B Apogee Acquisition
AbbVie ($ABBV) is reportedly nearing an $11 billion cash deal to acquire Apogee Therapeutics ($APGE), a biotechnology company focused on inflammatory diseases. The potential acquisition has drawn supp...
AbbVie would gain an experimental eczema drug by buying biotech: report
AbbVie is reportedly trying to buy a biotech company that is developing a promising atopic dermatitis drug for $10.9 billion in cash, according to a Financial Times report.
M&A News: AbbVie Lining up an $11B Deal for Eczema Drug Maker Apogee Therapeutics
Shares in biotechnology company Apogee Therapeutics ($APGE) are set to start the new week off in great shape on reports that it could be swallowed up for $11 billion by…
AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
AbbVie is nearing a deal to acquire inflammatory disease drug developer Apogee Therapeutics for about $10.9 billion in cash, the Financial Times reported on Friday, citing people familiar with the m...
AbbVie Declares Quarterly Dividend
NORTH CHICAGO, Ill., June 18, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share.
Allergan Aesthetics announces FDA approval of Skinvive by Juvederm
Allergan Aesthetics, an AbbVie (ABBV) company, announced the U.S. FDA approval of Skinvive by Juvederm to reduce neck lines for the improvement of neck appearance in adults over the age…
Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance
SKINVIVE by JUVÉDERM® is now the first and only hyaluronic acid injectable approved to reduce horizontal neck lines caused by "tech-neck.1" This is the second FDA-approved indication for SKINVIVE by J...
AbbVie presents new data on fixed-duration venetoclax-based combination at EHA
AbbVie (ABBV) announced new Phase 3 data on a fixed-duration venetoclax-based combination at the European Hematology Association, or EHA, 2026 Congress taking place June 11-14 in Stockholm, Sweden. Fi...